Improvement of periodontal status by green tea catechin using a local delivery system: a clinical pilot study.
The purpose of this study was to determine the usefulness of green tea catechin for the improvement of periodontal disease. The minimum inhibitory concentration (MIC) and bactericidal activity of green tea catechin against black-pigmented, Gram-negative anaerobic rods (BPR) were measured. Hydroxypropylcellulose strips containing green tea catechin as a slow release local delivery system were applied in pockets in patients once a week for 8 weeks. The clinical, enzymatic and microbiological effects of the catechin were determined. Green tea catechin showed a bactericidal effect against Porphyromonas gingivalis and Prevotella spp. in vitro with an MIC of 1.0 mg/ml. In the in vivo experiment, the pocket depth (PD) and the proportion of BPR were markedly decreased in the catechin group with mechanical treatment at week 8 compared with the baseline with significant difference. In contrast, PD and BPR were similar to the baseline and the value at the end of the experimental period in the placebo sites of scaled groups. The peptidase activities in the gingival fluid were maintained at lower levels during the experimental period in the test sites, while it reached 70% of that at baseline in the placebo sites. No morbidity was observed in the placebo and catechin groups without mechanical treatment. Green tea catechin showed a bactericidal effect against BPR and the combined use of mechanical treatment and the application of green tea catechin using a slow release local delivery system was effective in improving periodontal status.
Hirasawa
Masatomo
M
Department of Microbiology, Nihon University School of Dentistry at Matsudo, Matsudo, Chiba Japan. masahira@mascat.nihon-u.ac.jp
Takada
Kazuko
K
Makimura
Masaharu
M
Otake
Shigeo
S
D000287:Administration, Topical; D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D002392:Catechin / Q000008:administration & dosage / Q000627:therapeutic use*; D002482:Cellulose / Q000031:analogs & derivatives*; D003692:Delayed-Action Preparations; D012534:Dental Scaling; D016503:Drug Delivery Systems; D005260:Female; D005883:Gingival Crevicular Fluid / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010447:Peptide Hydrolases / Q000187:drug effects; D010514:Periodontal Pocket / Q000188:drug therapy / Q000382:microbiology; D010518:Periodontitis / Q000188:drug therapy* / Q000382:microbiology; D014677:Pharmaceutical Vehicles; D010865:Pilot Projects; D010919:Placebos; D016966:Porphyromonas gingivalis / Q000187:drug effects; D018720:Prevotella / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology; D016745:Root Planing; D013223:Statistics as Topic; D013662:Tea
D000900:Anti-Bacterial Agents; D000975:Antioxidants; D003692:Delayed-Action Preparations; D014677:Pharmaceutical Vehicles; D010919:Placebos; D011480:Protease Inhibitors; D013662:Tea; D002392:Catechin; D002482:Cellulose; C008079:hydroxypropylcellulose; D010447:Peptide Hydrolases